HNSCC
MCID: SQM013
MIFTS: 81

Squamous Cell Carcinoma, Head and Neck (HNSCC)

Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Squamous Cell Carcinoma, Head and Neck

MalaCards integrated aliases for Squamous Cell Carcinoma, Head and Neck:

Name: Squamous Cell Carcinoma, Head and Neck 57 13
Squamous Cell Carcinoma of the Head and Neck 12 53 25 74 29 6 15 72
Head and Neck Squamous Cell Carcinoma 12 53 25 15 17
Hnscc 57 53 25 74 55
Carcinoma, Squamous Cell of Head and Neck 75 53
Head and Neck Cancer 53 43
Squamous Cell Carcinoma of the Nasal Cavity and Paranasal Sinuses 59
Squamous Cell Carcinoma of the Nasal Cavity and Sinuses 59
Squamous Cell Carcinoma, Head and Neck, Somatic 57
Squamous Cell Carcinoma of the Hypopharynx 59
Squamous Cell Carcinoma of Salivary Glands 59
Squamous Cell Carcinoma of the Oral Cavity 59
Squamous Cell Carcinomas of Head and Neck 12
Squamous Cell Carcinoma of the Oropharynx 59
Carcinoma, Squamous Cell, Head and Neck 40
Salivary Gland Squamous Cell Carcinoma 17
Squamous Cell Carcinoma of the Larynx 59
Squamous Cell Carcinoma of the Lip 59
Carcinoma of the Head and Neck 12
Squamous Cell Carcinoma of Lip 72
Lip Squamous Cell Carcinoma 55
Cancer of Head and Neck 72
Cancer, Head/neck 40
Scchn 25

Characteristics:

OMIM:

57
Inheritance:
autosomal recessive


HPO:

32
squamous cell carcinoma, head and neck:
Inheritance autosomal recessive inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:5520
OMIM 57 275355
NCIt 50 C34447
MedGen 42 C1168401
UMLS 72 C0278996 C0280302 C1168401

Summaries for Squamous Cell Carcinoma, Head and Neck

Genetics Home Reference : 25 Squamous cell carcinoma is a cancer that arises from particular cells called squamous cells. Squamous cells are found in the outer layer of skin and in the mucous membranes, which are the moist tissues that line body cavities such as the airways and intestines. Head and neck squamous cell carcinoma (HNSCC) develops in the mucous membranes of the mouth, nose, and throat. HNSCC is classified by its location: it can occur in the mouth (oral cavity), the middle part of the throat near the mouth (oropharynx), the space behind the nose (nasal cavity and paranasal sinuses), the upper part of the throat near the nasal cavity (nasopharynx), the voicebox (larynx), or the lower part of the throat near the larynx (hypopharynx). Depending on the location, the cancer can cause abnormal patches or open sores (ulcers) in the mouth and throat, unusual bleeding or pain in the mouth, sinus congestion that does not clear, sore throat, earache, pain when swallowing or difficulty swallowing, a hoarse voice, difficulty breathing, or enlarged lymph nodes. HNSCC can spread (metastasize) to other parts of the body, such as the lymph nodes or lungs. If it spreads, the cancer has a worse prognosis and can be fatal. About half of affected individuals survive more than five years after diagnosis.

MalaCards based summary : Squamous Cell Carcinoma, Head and Neck, also known as squamous cell carcinoma of the head and neck, is related to squamous cell carcinoma and breast cancer, and has symptoms including tinnitus, halitosis and snoring. An important gene associated with Squamous Cell Carcinoma, Head and Neck is ING1 (Inhibitor Of Growth Family Member 1), and among its related pathways/superpathways are TGF-Beta Pathway and Phospholipase-C Pathway. The drugs Racepinephrine and Epinephrine have been mentioned in the context of this disorder. Affiliated tissues include lung, lymph node and salivary gland, and related phenotypes are squamous cell carcinoma and Decreased viability in esophageal squamous lineage

Disease Ontology : 12 A head and neck carcinoma that has material basis in squamous cells that line the moist, mucosal surfaces inside the head and neck.

NIH Rare Diseases : 53 Cancers that are known collectively as head and neck cancers usually begin in the squamous cells that line the moist, mucosal surfaces inside the head and neck (for example, inside the mouth, the nose, and the throat). These squamous cell cancers are often referred to as squamous cell carcinomas of the head and neck. At least 75 % of head and neck cancers are caused by tobacco and alcohol use. Infection with cancer-causing types of human papillomavirus (HPV), especially HPV-16, is a risk factor for some types of head and neck cancers. The symptoms of head and neck cancers may include a lump or a sore that does not heal, a sore throat that does not go away, difficulty in swallowing, and a change or hoarseness in the voice. Treatment for head and neck cancer can include surgery, radiation therapy, chemotherapy, targeted therapy, or a combination of treatments.

MedlinePlus : 43 Head and neck cancer includes cancers of the mouth, nose, sinuses, salivary glands, throat, and lymph nodes in the neck. Most begin in the moist tissues that line the mouth, nose, and throat. Symptoms include A lump or sore that does not heal A sore throat that does not go away Trouble swallowing A change or hoarseness in the voice Head and neck cancers are twice as common in men. Using tobacco or alcohol increases your risk. In fact, around 75 percent of head and neck cancers are linked to tobacco use, including smoking and smokeless tobacco. Infection with HPV is a risk factor for some head and neck cancers. To diagnose head and neck cancer, your doctor will do a physical exam and diagnostic tests. You will have a biopsy, where a sample of tissue is taken out and examined under a microscope. It is the only test that can tell for sure if you have cancer. If found early, these cancers are often curable. Treatments may include surgery, radiation therapy, chemotherapy, or a combination. Treatments can affect eating, speaking or even breathing, so patients may need rehabilitation. NIH: National Cancer Institute

UniProtKB/Swiss-Prot : 74 Squamous cell carcinoma of the head and neck: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes.

Wikipedia : 75 Squamous cell carcinomas (SCCs), also known as epidermoid carcinomas, comprise a number of different... more...

More information from OMIM: 275355

Related Diseases for Squamous Cell Carcinoma, Head and Neck

Diseases related to Squamous Cell Carcinoma, Head and Neck via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 836)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 33.2 TP53 SMAD4 PTEN PIK3CA MIR205 ING3
2 breast cancer 33.0 TP53 SMAD4 PTEN PIK3CA MIR98 MIR210
3 esophageal cancer 32.9 TP53 SMAD4 PTEN PIK3CA MIR21 MIR205
4 oral cavity cancer 32.8 TP53 TNFRSF10B PTEN PIK3CA
5 lung squamous cell carcinoma 32.7 TP53 PTEN PIK3CA NFE2L2 HRAS FGFR3
6 glioblastoma 32.7 TP53 PTEN PIK3CA MIR21 IDH2 HRAS
7 colorectal cancer 32.7 TP53 TNFRSF10B SMAD4 PTEN PIK3CA NFE2L2
8 hepatocellular carcinoma 32.6 TP53 SMAD4 PTEN PIK3CA NFE2L2 MIR21
9 cervical cancer 32.6 TP53 TNFRSF10B SMAD4 PTEN PIK3CA NFE2L2
10 prostate cancer 32.6 TP53 TNFRSF10B PTEN PIK3CA MIR210 MIR21
11 adenocarcinoma 32.5 TP53 SMAD4 PTEN PIK3CA HRAS H19
12 glioblastoma multiforme 32.5 TP53 PTEN PIK3CA MIR210 MIR21
13 bladder cancer 32.5 TP53 MIR21 MIR205 HRAS H19 FGFR3
14 pancreatic cancer 32.5 TP53 SMAD4 PIK3CA MIR210 MIR21 MIR205
15 melanoma 32.5 TP53 PTEN MIR210 MIR205 H19 BRAF
16 glioma 32.4 TP53 PTEN PIK3CA MIR210 MIR21 IDH2
17 ovarian cancer 32.4 TP53 TNFRSF10B PTEN PIK3CA MIR210 MIR21
18 gastric cancer 32.4 TP53 SMAD4 PTEN PIK3CA MIR21 H19
19 lung cancer 32.3 TP53 TNFRSF10B PTEN PIK3CA MIR98 MIR210
20 breast adenocarcinoma 32.3 TP53 SMAD4 PTEN PIK3CA H19
21 skin squamous cell carcinoma 32.2 TP53 PIK3CA MAP2K2 HRAS
22 lung cancer susceptibility 3 32.2 TP53 SMAD4 PIK3CA NFE2L2 HRAS H19
23 gastric adenocarcinoma 32.2 TP53 SMAD4 PTEN PIK3CA MAP2K2 HRAS
24 large intestine cancer 32.2 TP53 TNFRSF10B SMAD4 PTEN PIK3CA IDH2
25 leukemia, acute myeloid 32.2 TP53 MIR210 MIR21 IDH2 HRAS
26 adenoma 32.2 TP53 SMAD4 GNAS BRAF
27 myeloma, multiple 32.0 TP53 IDH2 HRAS H19 FGFR3 BRAF
28 endometrial cancer 32.0 TP53 PTEN PIK3CA HRAS H19 BRAF
29 brain cancer 32.0 TP53 PTEN PIK3CA IDH2 HRAS BRAF
30 carcinosarcoma 32.0 TP53 PTEN PIK3CA HRAS
31 transitional cell carcinoma 31.9 TP53 PTEN HRAS FGFR3 BRAF
32 melanoma, cutaneous malignant 1 31.9 TP53 PTEN PIK3CA HRAS BRAF
33 suppression of tumorigenicity 12 31.9 TP53 SMAD4 PTEN PIK3CA HRAS BRAF
34 kidney cancer 31.9 TP53 MIR210 MIR21 H19
35 adenoid cystic carcinoma 31.8 TP53 PTEN PIK3CA HRAS
36 differentiated thyroid carcinoma 31.8 TP53 HRAS BRAF
37 colorectal adenocarcinoma 31.8 TP53 HRAS BRAF
38 bladder urothelial carcinoma 31.8 TP53 PIK3CA NFE2L2 HRAS FGFR3 BRAF
39 laryngeal squamous cell carcinoma 31.7 TP53 MIR21 H19
40 small cell cancer of the lung 31.7 TP53 PTEN PIK3CA MIR21
41 clear cell renal cell carcinoma 31.6 TP53 PTEN MIR21 CYTOR
42 ovary adenocarcinoma 31.6 TP53 PIK3CA HRAS
43 medulloblastoma 31.6 TP53 TNFRSF10B PTEN PIK3CA H19
44 tongue squamous cell carcinoma 31.5 TP53 MIR21 CYTOR
45 ovarian epithelial cancer 31.4 PIK3CA H19
46 nasopharyngeal carcinoma 31.2 TP53 PIK3CA HRAS H19
47 thyroid gland cancer 11.8
48 cheilitis glandularis 11.7
49 cholangiocarcinoma 11.4 TP53 SMAD4 PTEN PIK3CA MIR21 IDH2
50 renal cell carcinoma, papillary, 1 11.4 TP53 PTEN PIK3CA NFE2L2 HRAS FGFR3

Graphical network of the top 20 diseases related to Squamous Cell Carcinoma, Head and Neck:



Diseases related to Squamous Cell Carcinoma, Head and Neck

Symptoms & Phenotypes for Squamous Cell Carcinoma, Head and Neck

Human phenotypes related to Squamous Cell Carcinoma, Head and Neck:

32
# Description HPO Frequency HPO Source Accession
1 squamous cell carcinoma 32 HP:0002860

Symptoms via clinical synopsis from OMIM:

57
Lab:
beta family transforming growth factor resistance

Clinical features from OMIM:

275355

UMLS symptoms related to Squamous Cell Carcinoma, Head and Neck:


tinnitus, halitosis, snoring, sore throat, coughing, vertigo/dizziness, equilibration disorder

GenomeRNAi Phenotypes related to Squamous Cell Carcinoma, Head and Neck according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.7 BRAF FGFR3 GNAS HRAS IDH2 ING1
2 Decreased cell migration GR00055-A-1 9.65 BRAF FGFR3 HRAS MAP2K2 PIK3CA
3 Reduced mammosphere formation GR00396-S 9.23 BRAF GNAS H19 HRAS IDH2 NFE2L2
4 Decreased sensitivity to paclitaxel GR00112-A-0 9.16 PTEN SMAD4

MGI Mouse Phenotypes related to Squamous Cell Carcinoma, Head and Neck:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.24 BRAF FGFR3 GNAS HRAS ING1 MAP2K2
2 cardiovascular system MP:0005385 10.18 BRAF GNAS HRAS IDH2 MAP2K2 NFE2L2
3 neoplasm MP:0002006 10.1 BRAF FGFR3 GNAS HRAS IDH2 ING1
4 integument MP:0010771 10.07 BRAF FGFR3 GNAS HRAS MAP2K2 NFE2L2
5 craniofacial MP:0005382 10.06 BRAF FGFR3 GNAS HRAS MAP2K2 NFE2L2
6 endocrine/exocrine gland MP:0005379 10.06 BRAF GNAS HRAS ING1 MAP2K2 PIK3CA
7 adipose tissue MP:0005375 10.05 BRAF GNAS MAP2K2 NFE2L2 PIK3CA PTEN
8 digestive/alimentary MP:0005381 10.03 BRAF FGFR3 HRAS MAP2K2 NFE2L2 PTEN
9 normal MP:0002873 9.91 BRAF FGFR3 GNAS HRAS MAP2K2 NFE2L2
10 renal/urinary system MP:0005367 9.76 BRAF FGFR3 GNAS HRAS NFE2L2 PTEN
11 respiratory system MP:0005388 9.5 BRAF FGFR3 GNAS HRAS NFE2L2 PTEN
12 skeleton MP:0005390 9.32 BRAF FGFR3 GNAS HRAS MAP2K2 NFE2L2

Drugs & Therapeutics for Squamous Cell Carcinoma, Head and Neck

Drugs for Squamous Cell Carcinoma, Head and Neck (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 669)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Racepinephrine Approved Phase 4 329-65-7 838
2
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
3
Cevimeline Approved Phase 4 107233-08-9 25137844 83898
4
Norepinephrine Approved Phase 4 51-41-2 439260
5
Methadone Approved, Illicit Phase 4 76-99-3 4095
6
Citalopram Approved Phase 4 59729-33-8 2771
7
Dobutamine Approved Phase 4 34368-04-2 36811
8
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
9
Meperidine Approved Phase 4 57-42-1 4058
10
Dopexamine Approved, Investigational Phase 4 86197-47-9 55483
11
Raltitrexed Approved, Investigational Phase 4 112887-68-0 104758
12
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
13
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
14
Nicotine Approved Phase 4 54-11-5 942 89594
15
Hydrocodone Approved, Illicit, Investigational Phase 4 125-29-1 5284569
16
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
17
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
18
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
19
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
20
Acetaminophen Approved Phase 4 103-90-2 1983
21
Morphine Approved, Investigational Phase 4 57-27-2 5288826
22
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
23
Tyrosine Approved, Investigational, Nutraceutical Phase 4 60-18-4 6057
24 Sympathomimetics Phase 4
25 Adrenergic Agonists Phase 4
26 Epinephryl borate Phase 4
27 Adrenergic beta-Agonists Phase 4
28 Adrenergic alpha-Agonists Phase 4
29 Mydriatics Phase 4
30 Adrenergic Agents Phase 4
31 Vasoconstrictor Agents Phase 4
32 Anti-Asthmatic Agents Phase 4
33 Bronchodilator Agents Phase 4
34 Muscarinic Agonists Phase 4
35 Parasympatholytics Phase 4
36 Serotonin Uptake Inhibitors Phase 4
37 Cholinergic Antagonists Phase 4
38 Muscarinic Antagonists Phase 4
39 Cardiotonic Agents Phase 4
40 Dopamine agonists Phase 4
41 Neurotransmitter Agents Phase 4
42 Respiratory System Agents Phase 4
43 Autonomic Agents Phase 4
44 Acidophilus Phase 4
45 Antipyretics Phase 4
46 Cholinergic Agents Phase 4
47 Psychotropic Drugs Phase 4
48 Central Nervous System Stimulants Phase 4
49 Anesthetics, Intravenous Phase 4
50 Narcotics Phase 4

Interventional clinical trials:

(show top 50) (show all 2328)
# Name Status NCT ID Phase Drugs
1 Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® Unknown status NCT01553032 Phase 4 Erbitux®
2 Randomized Phase IV Trial to Compare Cetuximab With Concomitant Radiation Therapy With Concomitant Mitomycin-C and 5-Fluorouracil With Radiation Therapy for Locally Advanced Squamous Cell Carcinomas of the Head and Neck Unknown status NCT02015650 Phase 4 Cetuximab;Mitomycin-C/ 5-Fluorouracil
3 EVALUATION OF THE USE OF N-ACETYLCYSTEINE ATTENUATING CISPLATIN-INDUCED TOXICITIES BY OXIDATIVE STRESS IN HEAD AND NECK CANCER PATIENTS Unknown status NCT02241876 Phase 4 N-acetylcysteine
4 Effectiveness of Low Energy Laser Treatment in Oral Mucositis Induced by Chemotherapy and Radiotherapy in Head and Neck Cancer Unknown status NCT01876407 Phase 4
5 Pharmacokinetics and Pharmacogenetics-based Adaptive Dosing of 5-fu (5-Fluorouracile) in Head & Neck Cancer Patient Undergoing Docetaxel, Cisplatin, 5-Fluorouracile (=TPF) Therapy Unknown status NCT02484677 Phase 4 Cisplatin;Docetaxel;5-Fluorouracile
6 Open-Label, Multi-Center, Randomized, Active-Controlled, Phase 4 Study of rAd-p53 Gene Therapy Combined With Chemotherapy and Radiotherapy in Treament of Head and Neck Cancer in Advanced Stage Unknown status NCT00894153 Phase 4 chemotherapy plus p53;chemotherapy
7 The Prevention of Refeeding Syndrome by a Diet Regime in Patient With Head and Neck Cancer Unknown status NCT01845922 Phase 4
8 Comparison Between Two Regimens of Chemotherapy Concurrent With Radiotherapy in Locally Advanced Head and Neck Cancer Completed NCT03998696 Phase 4 Cisplatin 40 mg/m2;Cisplatin 100 mg/m2
9 Phase IV Trial to Use Stereotactic Body Radiotherapy for Head and Neck Tumors Completed NCT01344356 Phase 4
10 An Investigator-Initiated,Multicenter,Randomized,Double-Blind Placebo-Controlled Design Study to Assess the Effectiveness of CeviMeline to Improve OraL Health in Patients With XErostomia Secondary to Radiation Therapy for Treatment of Head and Neck Squamous Cell Carcinoma Completed NCT00466388 Phase 4 Cevimeline
11 An Open-Label Study Using the Medpulser® Electroporation System to Treat Head and Neck Cancer Completed NCT00198263 Phase 4
12 Treatment of Pain in Head-and-Neck Cancer Patients: is Methadone More Effective Than Fentanyl? Completed NCT01317589 Phase 4 fentanyl;methadone
13 Prevention of Depression in Patients Being Treated for Head and Neck Cancer Completed NCT00536172 Phase 4 Escitalopram;Placebo
14 The Multi-center,Open-label,Single Arm Phase IV Clinical Trial of Efficacy and Safety of PEG-rhG-CSF in Patients With Lung Cancer,Head and Neck Cancer,Colorectal Cancer,Ovarian Cancer and the Other Cancer Receiving Chemotherapy Completed NCT02805166 Phase 4 PEG-rhG-CSF
15 The Effect of Norepinephrine and Dopamine on Radial Forearm Free Flap Tissue Oxygen Pressure and Microdialysate Metabolite Measurements Completed NCT02241083 Phase 4 Dopamine;Norepinephrine
16 A Randomized, Double-blind Study to Evaluate the Efficacy of MuGard Mucoadhesive Oral Wound Rinse for the Amelioration of Oral Mucositis in Subjects Receiving Chemoradiation Therapy for the Treatment of Cancers of the Head and Neck Completed NCT01283906 Phase 4
17 Clinical Evaluation of a Salivary Substitute and a Mucoprotective Product on Xerostomia in Head-and-neck Cancer Patients Completed NCT01316393 Phase 4
18 A Prospective Randomized Study of LigaSure Small Jaw® Versus Conventional Neck Dissection in Head and Neck Cancer Patients Completed NCT02597582 Phase 4
19 Effect of Enteral Immunonutrition During Chemoradiotherapy in Patients With Head and Neck Cancer or Esophageal Cancer Completed NCT00333099 Phase 4
20 A Clinical Trial of ALA Photodynamic Therapy for Treatment of Actinic Cheilitis in Patients With Squamous Cell Carcinoma of the Lip. Completed NCT00868088 Phase 4
21 Preloading Magnesium Attenuate Cisplatin-induced Nephrotoxicity Completed NCT02481518 Phase 4 Magnesium
22 An Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery: A Randomised Study Completed NCT01418118 Phase 4 Epinephrine;Norepinephrine;Dobutamine;Dopexamine
23 Perioperative Gabapentin Use In Head And Neck Mucosal Surgery Patients: A Randomized Clinical Trial Completed NCT02926573 Phase 4 Gabapentin;Placebo
24 Advances in the Management of Mandibular Osteoradionecrosis: Pentoxifylline and Tocopherol as Medical Treatment Completed NCT02368457 Phase 4 Pentoxifylline and Tocopherol
25 Absorption of Orally Ingested Phosphate in Head and Neck Cancer Patients With and Without Refeeding Syndrome Completed NCT02880072 Phase 4
26 Radiotherapy Combine With Raltitrexed Versus Radiotherapy Alone in Older Patients With Head and Neck Squamous Cell Carcinoma: a Prospective Randomized Controlled Trial Recruiting NCT03196843 Phase 4 Raltitrexed
27 Does Continuous Popliteal Nerve Block Improve Pain Management for Patients Undergoing Major Maxilla or Mandible Resection With Microvascular Reconstruction Using a Free Fibula Graft Recruiting NCT03607227 Phase 4 Levobupivacaine;Saline Solution
28 A Randomized Placebo-controlled Pilot Study of Single-dose Intraoperative Ketamine for the Prevention of Delirium in Otolaryngeal Cancer Surgery Patients Recruiting NCT03040024 Phase 4 Ketamine;Placebo
29 Pain Management in Head and Neck Surgery Patients Recruiting NCT03121963 Phase 4 Oxycodone;Acetaminophen;Gabapentin;Celecoxib;Hydrocodone-Acetaminophen
30 A Randomized Study on the Effects of Lactobacillus Brevis CD2 in the Prevention of Radio and Chemotherapy Induced Oral Mucositis in Head and Neck Cancer Patients. Recruiting NCT01707641 Phase 4
31 Implementation Strategies to Improve Tobacco Treatment for UF Health Cancer Center Patients Recruiting NCT03482583 Phase 4 Nicotine Replacement Therapy
32 Use of Single Dose Pre-Operative Pregabalin for Post-Operative Analgesia in Bilateral Head and Neck Cancer Surgery: A Randomized, Double-Blinded, Placebo-Controlled Trial Enrolling by invitation NCT03714867 Phase 4 Pregabalin 150mg
33 A Single Arm, Multi-center Study to Assess the Efficacy and Safety of Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in Non-squamous Non-small-cell Lung Cancer (NSCLC) Not yet recruiting NCT03799601 Phase 4 Anlotinib;Docetaxel;Carboplatin
34 Prospective, Open-label, Randomized, Control Study of Head and Neck Cancer Radiation Treatment With or Without Amifostine Suspended NCT01288625 Phase 4 Amifostine
35 Determination of the Optimal Infusion Rate of Amino Acids in Seriously Ill Patients Terminated NCT01923480 Phase 4 15% CLINISOL - Sulfite-free (Amino Acid) Injection;15% CLINISOL - Sulfite-free (Amino Acid) Injection;15% CLINISOL - Sulfite-free (Amino Acid) Injection
36 Radiotherapy Dose Escalation in Locally Advanced Squamous Cell Carcinoma of the Larynx or Hypopharynx Withdrawn NCT03388931 Phase 4
37 Phase II GENIUS Trial of GENetically-Informed Therapies for Patients With previoUSly Treated Refractory Metastatic Cancer Withdrawn NCT02000739 Phase 4
38 Controlled Randomized Trial to Evaluate Efficacy of Adjuvant Chemotherapy Between S-1 and UFT for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Phase III Study Unknown status NCT00336947 Phase 3 tegafur-gimeracil-oteracil potassium;tegafur-uracil
39 A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFECT OF CISPLATIN/EPINEPHRINE INJECTABLE GEL (PRODUCT MPI 5010) WHEN ADMINISTERED INTRATUMORALLY FOR ACHIEVEMENT OF TREATMENT GOALS IN RECURRENT OR REFRACTORY SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK Unknown status NCT00002659 Phase 3 cisplatin-e therapeutic implant
40 A Multi-centre Randomised Phase III Trial Comparing PET-CT Guided Watch and Wait Policy Versus Planned Neck Dissection for the Management of Locally Advanced (N2/N3) Nodal Metastases in Patients With Head and Neck Squamous Cancer Unknown status NCT00720070 Phase 3
41 A Phase III Trial of Concurrent Radiation and Chemotherapy for Advanced Head and Neck Carcinomas Unknown status NCT00047008 Phase 3 cisplatin
42 Multicentre Randomised Trial of Inductive and Adjuvant Perilymphatically Injected Proleukin (rlL-2) in The Treatment of Operable Primary Squamous Cell Carcinoma of The Oral Cavity and Oropharynx Unknown status NCT00002702 Phase 3
43 RANDOMIZED TRIAL OF NEOADJUVANT CHEMOTHERAPY AND SURGERY +/- RADIOTHERAPY VERSUS SURGEERY +/- RADIOTHERAPY IN OPERABLE SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY Unknown status NCT00002747 Phase 3 cisplatin;fluorouracil
44 A Randomized, Open-label, Multi-center Phase III Study Designed to Evaluate the Safety and Efficacy of E10A in Patients With Recurrent/Unresectable Squamous Cell Carcinoma of the Head and Neck Region Unknown status NCT02630264 Phase 3 Endostatins;Paclitaxel injection;Cisplatin injection
45 A Multicentre Randomised Study Of Parotid Sparing Intensity Modulated Radiotherapy Versus Conventional Radiotherapy In Patients With Head And Neck Cancer Unknown status NCT00081029 Phase 3
46 Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone Unknown status NCT00041626 Phase 3
47 Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate Unknown status NCT00041613 Phase 3
48 Phase III Randomized Study of Radiotherapy With or Without Cisplatin and Fluorouracil for Locally Advanced, Nonresectable Squamous Cell Cancer of the Oropharynx or Hypopharynx Unknown status NCT00003627 Phase 3 cisplatin;fluorouracil
49 Randomised Clinical Phase III Study of Radiotherapy Dose, Volume Evaluation for 3DCRT Versus IGRT and Analysis of Early Response in Head and Neck Squamous Cell Carcinoma Unknown status NCT01124409 Phase 3
50 Relationship Between Changes in Body Composition and Supplementation With EPA in Patients Diagnosed With Squamous Cell Carcinoma of Head and Neck Locally Advanced (Stage III-IVb) Unknown status NCT02715596 Phase 3

Search NIH Clinical Center for Squamous Cell Carcinoma, Head and Neck

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Bleomycin
Cisplatin
Hydroxyurea
Ifosfamide
Methotrexate
Mitomycin
Technetium Tc-99m tilmanocept

Genetic Tests for Squamous Cell Carcinoma, Head and Neck

Genetic tests related to Squamous Cell Carcinoma, Head and Neck:

# Genetic test Affiliating Genes
1 Squamous Cell Carcinoma of the Head and Neck 29 ING1 TNFRSF10B

Anatomical Context for Squamous Cell Carcinoma, Head and Neck

MalaCards organs/tissues related to Squamous Cell Carcinoma, Head and Neck:

41
Lung, Lymph Node, Salivary Gland, Skin, Thyroid, Testes, Breast

Publications for Squamous Cell Carcinoma, Head and Neck

Articles related to Squamous Cell Carcinoma, Head and Neck:

(show top 50) (show all 4439)
# Title Authors PMID Year
1
Detection of new PTEN/MMAC1 mutations in head and neck squamous cell carcinomas with loss of chromosome 10. 8 71
11801303 2002
2
Genomic structure of the human ING1 gene and tumor-specific mutations detected in head and neck squamous cell carcinomas. 8 71
10866301 2000
3
Rare loss-of-function mutation of a death receptor gene in head and neck cancer. 8 71
9721851 1998
4
Comprehensive genomic characterization of head and neck squamous cell carcinomas. 8
25631445 2015
5
The mutational landscape of head and neck squamous cell carcinoma. 8
21798893 2011
6
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. 8
21798897 2011
7
Network modeling identifies molecular functions targeted by miR-204 to suppress head and neck tumor metastasis. 38 88
20369013 2010
8
Identification of a microRNA signature associated with progression of leukoplakia to oral carcinoma. 8
19776030 2009
9
An expression profile for diagnosis of lymph node metastases from primary head and neck squamous cell carcinomas. 8
15640797 2005
10
Defects in cell growth regulation by C18:0-ceramide and longevity assurance gene 1 in human head and neck squamous cell carcinomas. 8
15317812 2004
11
Functional evidence for a squamous cell carcinoma mortality gene(s) on human chromosome 4. 8
12140764 2002
12
Microsatellite alterations in serum DNA of head and neck cancer patients. 8
8782464 1996
13
Resistance of human squamous carcinoma cells to transforming growth factor beta 1 is a recessive trait. 8
8327510 1993
14
Head and neck cancer in living donor liver transplant recipients: Single center retrospective study. 17
31374062 2019
15
Examining tumor modulating effects of photobiomodulation therapy on head and neck squamous cell carcinomas. 17
31197302 2019
16
Two Sides of the Same Coin: Head and Neck Cancer Treatment De-Intensification and Intensification with Induction Chemotherapy. 17
31200811 2018
17
New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors. 9 38
20406834 2010
18
Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. 88
19782034 2009
19
MicroRNA expression ratio is predictive of head and neck squamous cell carcinoma. 88
19351747 2009
20
Genetic polymorphisms in DNA base excision repair gene XRCC1 and the risk of squamous cell carcinoma of the head and neck. 9 38
19284666 2009
21
Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma. 9 38
19240170 2009
22
Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma. 88
19179615 2009
23
MicroRNA alterations in head and neck squamous cell carcinoma. 88
18798260 2008
24
Detection of metastatic head and neck squamous cell carcinoma using the relative expression of tissue-specific mir-205. 88
19043531 2008
25
The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck. 9 38
18997665 2008
26
Identification of the rare EGFR mutation p.G796S as somatic and germline mutation in white patients with squamous cell carcinoma of the head and neck. 9 38
18528899 2008
27
A genotype-phenotype examination of cyclin D1 on risk and outcome of squamous cell carcinoma of the head and neck. 9 38
18413827 2008
28
Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck. 9 38
18223210 2008
29
STAT3 signaling is induced by intercellular adhesion in squamous cell carcinoma cells. 9 38
17961551 2008
30
The role of genetic factor in etiopathogenesis of squamous cell carcinoma of the head and neck in young adults. 9 38
17653748 2007
31
P53 codon 72 polymorphism in squamous cell carcinoma of the head and neck region. 9 38
17970074 2007
32
MicroRNA expression profiles in head and neck cancer cell lines. 88
17475218 2007
33
Loss of p53 expression correlates with metastatic phenotype and transcriptional profile in a new mouse model of head and neck cancer. 9 38
17426250 2007
34
Detection of human papillomavirus-16 in fine-needle aspirates to determine tumor origin in patients with metastatic squamous cell carcinoma of the head and neck. 9 38
17317828 2007
35
EGFR mutations and human papillomavirus in squamous cell carcinoma of tongue and tonsil. 9 38
17224267 2007
36
High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. 88
17222355 2007
37
EphB4 provides survival advantage to squamous cell carcinoma of the head and neck. 9 38
16615113 2006
38
Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma. 9 38
16618910 2006
39
Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis. 9 38
16551875 2006
40
Association between high collagenase-3 expression levels and poor prognosis in patients with head and neck cancer. 9 38
16302191 2006
41
SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition. 9 38
16007169 2005
42
A study of TRAIL receptors in squamous cell carcinoma of the head and neck. 9 38
15897419 2005
43
The effect of tetrathiomolybdate on cytokine expression, angiogenesis, and tumor growth in squamous cell carcinoma of the head and neck. 9 38
15781759 2005
44
Function and importance of p63 in normal oral mucosa and squamous cell carcinoma of the head and neck. 9 38
15608417 2005
45
Chemokine receptors 6 and 7 identify a metastatic expression pattern in squamous cell carcinoma of the head and neck. 9 38
15608423 2005
46
Real-time expression profiling of microRNA precursors in human cancer cell lines. 88
16192569 2005
47
Phase II trial of cisplatin and capecitabine in patients with squamous cell carcinoma of the head and neck, and correlative study of angiogenic factors. 9 38
15597103 2004
48
Expression of c-erbB receptors, MMPs and VEGF in squamous cell carcinoma of the head and neck. 9 38
15254682 2004
49
Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck. 9 38
14729608 2004
50
Polymorphisms of GSTT1 and related genes in head and neck cancer risk. 9 38
14724908 2004

Variations for Squamous Cell Carcinoma, Head and Neck

ClinVar genetic disease variations for Squamous Cell Carcinoma, Head and Neck:

6 (show top 50) (show all 344)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 TP53 NM_000546.5(TP53): c.832C> A (p.Pro278Thr) single nucleotide variant Likely pathogenic,drug response rs17849781 17:7577106-7577106 17:7673788-7673788
2 EGFR NM_005228.5(EGFR): c.2155G> C (p.Gly719Arg) single nucleotide variant Likely pathogenic,drug response rs28929495 7:55241707-55241707 7:55174014-55174014
3 PIK3CA NM_006218.4(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic rs121913281 3:178952084-178952084 3:179234296-179234296
4 TP53 NM_000546.5(TP53): c.422G> A (p.Cys141Tyr) single nucleotide variant Pathogenic rs587781288 17:7578508-7578508 17:7675190-7675190
5 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic rs587778720 17:7578211-7578211 17:7674893-7674893
6 SMAD4 NM_005359.5(SMAD4): c.1082G> A (p.Arg361His) single nucleotide variant Pathogenic rs377767347 18:48591919-48591919 18:51065549-51065549
7 PIK3CA NM_006218.4(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 3:178936092-178936092 3:179218304-179218304
8 TP53 NM_000546.5(TP53): c.818G> T (p.Arg273Leu) single nucleotide variant Pathogenic rs28934576 17:7577120-7577120 17:7673802-7673802
9 TP53 NM_000546.5(TP53): c.517G> T (p.Val173Leu) single nucleotide variant Pathogenic rs876660754 17:7578413-7578413 17:7675095-7675095
10 TNFRSF10B TNFRSF10B, 2-BP INS insertion Pathogenic
11 PTEN NM_000314.7(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 10:89692905-89692905 10:87933148-87933148
12 PTEN NM_000314.7(PTEN): c.362C> G (p.Ala121Gly) single nucleotide variant Pathogenic rs121909237 10:89692878-89692878 10:87933121-87933121
13 ING1 NM_198217.2(ING1): c.512G> C (p.Cys171Ser) single nucleotide variant Pathogenic rs121909250 13:111372083-111372083 13:110719736-110719736
14 ING1 NM_198217.2(ING1): c.515A> G (p.Asn172Ser) single nucleotide variant Pathogenic rs121909251 13:111372086-111372086 13:110719739-110719739
15 ING1 NM_198217.2(ING1): c.443C> A (p.Ala148Asp) single nucleotide variant Pathogenic rs121909252 13:111372014-111372014 13:110719667-110719667
16 MAP2K2 NM_030662.3(MAP2K2): c.169T> G (p.Phe57Val) single nucleotide variant Pathogenic rs121434498 19:4117551-4117551 19:4117553-4117553
17 SMAD4 NM_005359.5(SMAD4): c.1081C> T (p.Arg361Cys) single nucleotide variant Pathogenic rs80338963 18:48591918-48591918 18:51065548-51065548
18 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 17:7577539-7577539 17:7674221-7674221
19 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 17:7577548-7577548 17:7674230-7674230
20 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic rs121912655 17:7577556-7577556 17:7674238-7674238
21 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 17:7577547-7577547 17:7674229-7674229
22 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 17:7577548-7577548 17:7674230-7674230
23 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 17:7578190-7578190 17:7674872-7674872
24 HRAS NM_005343.4(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 11:534289-534289 11:534289-534289
25 HRAS NM_005343.4(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 11:534288-534288 11:534288-534288
26 HRAS NM_005343.4(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 11:534286-534286 11:534286-534286
27 HRAS NM_005343.4(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 11:534289-534289 11:534289-534289
28 PIK3CA NM_006218.4(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 3:178952085-178952085 3:179234297-179234297
29 PIK3CA NM_006218.4(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 3:178952085-178952085 3:179234297-179234297
30 BRAF NM_004333.6(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 7:140453136-140453136 7:140753336-140753336
31 BRAF NM_004333.6(BRAF): c.1781A> G (p.Asp594Gly) single nucleotide variant Pathogenic rs121913338 7:140453154-140453154 7:140753354-140753354
32 IDH2 NM_002168.3(IDH2): c.419G> A (p.Arg140Gln) single nucleotide variant Pathogenic rs121913502 15:90631934-90631934 15:90088702-90088702
33 FGFR3 NM_000142.4(FGFR3): c.742C> T (p.Arg248Cys) single nucleotide variant Pathogenic rs121913482 4:1803564-1803564 4:1801837-1801837
34 FGFR3 NM_000142.4(FGFR3): c.746C> G (p.Ser249Cys) single nucleotide variant Pathogenic rs121913483 4:1803568-1803568 4:1801841-1801841
35 PIK3CA NM_006218.4(PIK3CA): c.1637A> G (p.Gln546Arg) single nucleotide variant Pathogenic rs397517201 3:178936095-178936095 3:179218307-179218307
36 TP53 NM_000546.5(TP53): c.488A> G (p.Tyr163Cys) single nucleotide variant Pathogenic rs148924904 17:7578442-7578442 17:7675124-7675124
37 TP53 NM_000546.5(TP53): c.659A> G (p.Tyr220Cys) single nucleotide variant Pathogenic rs121912666 17:7578190-7578190 17:7674872-7674872
38 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic rs28934574 17:7577094-7577094 17:7673776-7673776
39 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic rs587781525 17:7577096-7577096 17:7673778-7673778
40 TP53 NM_000546.5(TP53): c.706T> G (p.Tyr236Asp) single nucleotide variant Pathogenic rs587782289 17:7577575-7577575 17:7674257-7674257
41 TP53 NM_000546.5(TP53): c.584T> C (p.Ile195Thr) single nucleotide variant Pathogenic rs760043106 17:7578265-7578265 17:7674947-7674947
42 TP53 NM_000546.5(TP53): c.833C> T (p.Pro278Leu) single nucleotide variant Pathogenic rs876659802 17:7577105-7577105 17:7673787-7673787
43 TP53 NM_000546.5(TP53): c.856G> A (p.Glu286Lys) single nucleotide variant Pathogenic rs786201059 17:7577082-7577082 17:7673764-7673764
44 PTEN NM_000314.7(PTEN): c.388C> G (p.Arg130Gly) single nucleotide variant Pathogenic rs121909224 10:89692904-89692904 10:87933147-87933147
45 TP53 NM_000546.5(TP53): c.713G> T (p.Cys238Phe) single nucleotide variant Pathogenic rs730882005 17:7577568-7577568 17:7674250-7674250
46 TP53 NM_000546.5(TP53): c.712T> C (p.Cys238Arg) single nucleotide variant Pathogenic rs1057519981 17:7577569-7577569 17:7674251-7674251
47 TP53 NM_000546.5(TP53): c.841G> T (p.Asp281Tyr) single nucleotide variant Pathogenic rs764146326 17:7577097-7577097 17:7673779-7673779
48 TP53 NM_000546.5(TP53): c.841G> A (p.Asp281Asn) single nucleotide variant Pathogenic rs764146326 17:7577097-7577097 17:7673779-7673779
49 PIK3CA NM_006218.4(PIK3CA): c.2176G> A (p.Glu726Lys) single nucleotide variant Pathogenic rs867262025 3:178938934-178938934 3:179221146-179221146
50 TP53 NM_000546.5(TP53): c.537T> G (p.His179Gln) single nucleotide variant Pathogenic rs876660821 17:7578393-7578393 17:7675075-7675075

UniProtKB/Swiss-Prot genetic disease variations for Squamous Cell Carcinoma, Head and Neck:

74
# Symbol AA change Variation ID SNP ID
1 ING1 p.Ala335Asp VAR_017420
2 ING1 p.Cys358Ser VAR_017421
3 ING1 p.Asn359Ser VAR_017422
4 ING3 p.Asp20Gly VAR_021263
5 PTEN p.Ala121Gly VAR_018103 rs121909237

Cosmic variations for Squamous Cell Carcinoma, Head and Neck:

9 (show top 50) (show all 313)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM10662 TP53 skin,neck,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 12
2 COSM607136 TGFBR1 skin,neck,carcinoma,squamous cell carcinoma c.1247C>T p.S416F 9:99146601-99146601 12
3 COSM6962965 SMO skin,neck,carcinoma,squamous cell carcinoma c.1103C>T p.P368L 7:129206332-129206332 12
4 COSM6962990 RARA skin,neck,carcinoma,squamous cell carcinoma c.1384C>T p.P462S 17:40356221-40356221 12
5 COSM6962984 RAD52 skin,neck,carcinoma,squamous cell carcinoma c.439G>A p.V147M 12:927173-927173 12
6 COSM6962994 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1607C>T p.S536L 20:42352239-42352239 12
7 COSM6962992 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1619G>A p.G540E 20:42352227-42352227 12
8 COSM456125 PTPRD skin,neck,carcinoma,squamous cell carcinoma c.5048C>T p.S1683F 9:8341168-8341168 12
9 COSM1700914 PTPRD skin,neck,carcinoma,squamous cell carcinoma c.1261C>T p.P421S 9:8518130-8518130 12
10 COSM6962970 PTPRD skin,neck,carcinoma,squamous cell carcinoma c.1736G>A p.S579N 9:8504347-8504347 12
11 COSM6962989 PLCG2 skin,neck,carcinoma,squamous cell carcinoma c.115G>T p.E39* 16:81786104-81786104 12
12 COSM6962964 PIK3CG skin,neck,carcinoma,squamous cell carcinoma c.3227G>A p.R1076K 7:106905305-106905305 12
13 COSM6962963 PIK3CG skin,neck,carcinoma,squamous cell carcinoma c.310G>A p.G104R 7:106867871-106867871 12
14 COSM564 NRAS skin,neck,carcinoma,squamous cell carcinoma c.35G>A p.G12D 1:114716126-114716126 12
15 COSM6962996 NCOA3 skin,neck,carcinoma,squamous cell carcinoma c.979C>T p.H327Y 20:47634062-47634062 12
16 COSM4170532 MTOR skin,neck,carcinoma,squamous cell carcinoma c.3409G>A p.E1137K 1:11212464-11212464 12
17 COSM6962967 KMT2C skin,neck,carcinoma,squamous cell carcinoma c.11659C>T p.H3887Y 7:152158874-152158874 12
18 COSM6962983 KMT2A skin,neck,carcinoma,squamous cell carcinoma c.4377T>G p.C1459W 11:118488658-118488658 12
19 COSM498 HRAS skin,neck,carcinoma,squamous cell carcinoma c.182A>T p.Q61L 11:533874-533874 12
20 COSM6438927 HGF skin,neck,carcinoma,squamous cell carcinoma c.974C>T p.P325L 7:81729671-81729671 12
21 COSM6962960 FGFR3 skin,neck,carcinoma,squamous cell carcinoma c.2421A>G p.*807W 4:1807262-1807262 12
22 COSM6962980 FGFR2 skin,neck,carcinoma,squamous cell carcinoma c.2234C>T p.S745F 10:121483765-121483765 12
23 COSM6962962 EPHA7 skin,neck,carcinoma,squamous cell carcinoma c.2468G>A p.G823E 6:93254711-93254711 12
24 COSM5918388 EPHA5 skin,neck,carcinoma,squamous cell carcinoma c.2608G>A p.E870K 4:65348104-65348104 12
25 COSM6962957 EPHA3 skin,neck,carcinoma,squamous cell carcinoma c.632T>A p.M211K 3:89210338-89210338 12
26 COSM6946976 EPHA3 skin,neck,carcinoma,squamous cell carcinoma c.533G>A p.G178E 3:89210239-89210239 12
27 COSM6962956 CASP8 skin,neck,carcinoma,squamous cell carcinoma c.1382C>T p.T461I 2:201286485-201286485 12
28 COSM3713589 CASP8 skin,neck,carcinoma,squamous cell carcinoma c.1093C>T p.L365F 2:201285055-201285055 12
29 COSM21323 ATM skin,neck,carcinoma,squamous cell carcinoma c.1009C>T p.R337C 11:108247071-108247071 12
30 COSM6950941 APC skin,neck,carcinoma,squamous cell carcinoma c.536C>T p.S179F 5:112780794-112780794 12
31 COSM6962953 AKT3 skin,neck,carcinoma,squamous cell carcinoma c.1164-1G>A p.? 1:243545598-243545598 12
32 COSM6962993 skin,neck,carcinoma,squamous cell carcinoma c.1619G>A p.G540E 20:42352227-42352227 12
33 COSM99602 skin,neck,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 12
34 COSM1640830 skin,neck,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 12
35 COSM6962972 skin,neck,carcinoma,squamous cell carcinoma c.1727G>A p.S576N 9:8504347-8504347 12
36 COSM6962978 skin,neck,carcinoma,squamous cell carcinoma c.2237C>T p.S746F 10:121483765-121483765 12
37 COSM6962995 skin,neck,carcinoma,squamous cell carcinoma c.1607C>T p.S536L 20:42352239-42352239 12
38 COSM1350749 skin,neck,carcinoma,squamous cell carcinoma c.1009C>T p.R337C 11:108247071-108247071 12
39 COSM6962951 skin,neck,carcinoma,squamous cell carcinoma c.1164-1G>A p.? 1:243545598-243545598 12
40 COSM1700913 skin,neck,carcinoma,squamous cell carcinoma c.1261C>T p.P421S 9:8518130-8518130 12
41 COSM1700915 skin,neck,carcinoma,squamous cell carcinoma c.1252C>T p.P418S 9:8518130-8518130 12
42 COSM6962982 skin,neck,carcinoma,squamous cell carcinoma c.4377T>G p.C1459W 11:118488658-118488658 12
43 COSM6962950 skin,neck,carcinoma,squamous cell carcinoma c.430C>T p.P144S 1:77966737-77966737 12
44 COSM1700912 skin,neck,carcinoma,squamous cell carcinoma c.1261C>T p.P421S 9:8518130-8518130 12
45 COSM6962991 skin,neck,carcinoma,squamous cell carcinoma c.1369C>T p.P457S 17:40356221-40356221 12
46 COSM99020 skin,neck,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 12
47 COSM99021 skin,neck,carcinoma,squamous cell carcinoma c.464G>A p.R155Q 17:7674220-7674220 12
48 COSM6962979 skin,neck,carcinoma,squamous cell carcinoma c.1967C>T p.S656F 10:121483765-121483765 12
49 COSM6962969 skin,neck,carcinoma,squamous cell carcinoma c.1736G>A p.S579N 9:8504347-8504347 12
50 COSM6962971 skin,neck,carcinoma,squamous cell carcinoma c.1706G>A p.S569N 9:8504347-8504347 12

Copy number variations for Squamous Cell Carcinoma, Head and Neck from CNVD:

7 (show all 42)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 33952 1 50700000 61300000 Amplification head and neck squamous cell carcinoma
2 71135 12 67700000 71500000 Amplification head and neck squamous cell carcinoma
3 78639 13 55300000 73300000 Amplification head and neck squamous cell carcinoma
4 90904 15 25700000 28100000 Amplification head and neck squamous cell carcinoma
5 93784 15 59100000 59300000 Copy number MET head and neck squamous cell carcinoma
6 118006 17 7505821 7531588 LOH TP53 head and neck squamous cell carcinoma
7 119192 18 1 7100000 Amplification head and neck squamous cell carcinoma
8 119790 18 17200000 19000000 Amplification head and neck squamous cell carcinoma
9 166134 3 1 87900000 Loss head and neck squamous cell carcinoma
10 167635 3 121900000 167600000 Gain head and neck squamous cell carcinoma
11 169556 3 142800000 148900000 Amplification head and neck squamous cell carcinoma
12 171486 3 168801287 168851758 Amplification EVI1 head and neck squamous cell carcinoma
13 171495 3 168867391 169381563 Amplification MDS1 head and neck squamous cell carcinoma
14 172487 3 182700000 187900000 Amplification RFC4 head and neck squamous cell carcinoma
15 174746 12 7773277 7793336 Deletion DLEC head and neck squamous cell carcinoma
16 179443 3 91000000 121900000 Gain head and neck squamous cell carcinoma
17 179973 4 1 50400000 Loss head and neck squamous cell carcinoma
18 204736 6 114600000 171115067 Gain head and neck squamous cell carcinoma
19 217049 7 1 159138663 Copy number head and neck squamous cell carcinoma
20 225369 7 45400000 54000000 Gain EGFR head and neck squamous cell carcinoma
21 225383 7 45400000 54000000 Amplification EGFR head and neck squamous cell carcinoma
22 225403 7 45400000 54000000 Copy number EGFR head and neck squamous cell carcinoma
23 225404 7 45400000 54000000 Copy number EGFR head and neck squamous cell carcinoma
24 225408 7 45400000 54000000 Deletion or amplific ation EGFR head and neck squamous cell carcinoma
25 225413 7 45400000 58000000 Amplification head and neck squamous cell carcinoma
26 226532 7 58000000 59900000 Amplification head and neck squamous cell carcinoma
27 232747 8 119200000 122500000 Gain MYC head and neck squamous cell carcinoma
28 233769 8 127300000 139900000 Gain KHDRBS3 head and neck squamous cell carcinoma
29 234876 8 139900000 146364022 Gain FAK head and neck squamous cell carcinoma
30 234895 8 139900000 146364022 Gain PTP4A3 head and neck squamous cell carcinoma
31 238011 8 28800000 45600000 Amplification head and neck squamous cell carcinoma
32 239988 8 43100000 45600000 Amplification head and neck squamous cell carcinoma
33 240109 8 45600000 146364022 Gain GAA1 head and neck squamous cell carcinoma
34 241899 8 68000000 70500000 Amplification head and neck squamous cell carcinoma
35 243677 8 86900000 101600000 Amplification RUNX1T1 head and neck squamous cell carcinoma
36 249984 9 19900000 25500000 Deletion CDKN2A head and neck squamous cell carcinoma
37 300518 11 95351087 95715992 Methylation MAML2 head and neck squamous cell carcinoma
38 300530 12 123374913 123617963 Methylation NCOR2 head and neck squamous cell carcinoma
39 300892 14 72672931 72756862 Methylation PSEN1 head and neck squamous cell carcinoma
40 300893 14 72811670 72995039 Methylation NUMB head and neck squamous cell carcinoma
41 303261 20 10566331 10602694 Methylation JAG1 head and neck squamous cell carcinoma
42 302931 19 45863651 45888396 Methylation NUMBL head and neck squamous cell carcinoma

Expression for Squamous Cell Carcinoma, Head and Neck

LifeMap Discovery
Genes differentially expressed in tissues of Squamous Cell Carcinoma, Head and Neck patients vs. healthy controls: 35 (show all 15)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 MMP1 matrix metallopeptidase 1 Head Mesenchyme + 5.25 0.000
2 TMPRSS11B transmembrane protease, serine 11B Head Mesenchyme - 4.81 0.000
3 CRISP3 cysteine-rich secretory protein 3 Head Mesenchyme - 4.48 0.000
4 MAL mal, T-cell differentiation protein Head Mesenchyme - 4.39 0.000
5 INHBA inhibin, beta A Head Mesenchyme + 4.13 0.000
6 CRNN cornulin Head Mesenchyme - 4.00 0.000
7 KRT17 keratin 17, type I Head Mesenchyme + 3.94 0.000
8 KRT4 keratin 4, type II Head Mesenchyme - 3.41 0.000
9 PTHLH parathyroid hormone-like hormone Head Mesenchyme + 3.36 0.000
10 CTHRC1 collagen triple helix repeat containing 1 Head Mesenchyme + 3.32 0.000
11 CLCA4 chloride channel accessory 4 Head Mesenchyme - 3.31 0.000
12 WDR72 WD repeat domain 72 Head Mesenchyme + 3.23 0.000
13 MMP10 matrix metallopeptidase 10 Head Mesenchyme + 3.14 0.001
14 TGM3 transglutaminase 3 Head Mesenchyme - 3.08 0.000
15 GBP1 guanylate binding protein 1, interferon-inducible Head Mesenchyme + 3.06 0.000
Search GEO for disease gene expression data for Squamous Cell Carcinoma, Head and Neck.

Pathways for Squamous Cell Carcinoma, Head and Neck

Pathways related to Squamous Cell Carcinoma, Head and Neck according to GeneCards Suite gene sharing:

(show top 50) (show all 91)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.61 TP53 TNFRSF10B SMAD4 PIK3CA MAP2K2 HRAS
2
Show member pathways
13.13 TP53 PTEN MAP2K2 HRAS GNAS FGFR3
3
Show member pathways
13.04 TP53 PTEN PIK3CA MAP2K2 HRAS GNAS
4
Show member pathways
13.03 TP53 SMAD4 PTEN PIK3CA MAP2K2 HRAS
5
Show member pathways
13 TP53 TNFRSF10B PTEN PIK3CA MAP2K2 HRAS
6
Show member pathways
12.99 TP53 TNFRSF10B PIK3CA MAP2K2 HRAS GNAS
7
Show member pathways
12.91 PTEN PIK3CA MAP2K2 HRAS GNAS FGFR3
8
Show member pathways
12.89 TP53 SMAD4 PTEN PIK3CA MAP2K2 HRAS
9
Show member pathways
12.85 TP53 TNFRSF10B PIK3CA MAP2K2 HRAS
10
Show member pathways
12.83 PTEN PIK3CA MAP2K2 HRAS BRAF
11 12.81 TP53 MAP2K2 HRAS FGFR3 BRAF
12
Show member pathways
12.8 PIK3CA MAP2K2 HRAS GNAS FGFR3 BRAF
13
Show member pathways
12.78 TP53 PTEN PIK3CA HRAS FGFR3
14
Show member pathways
12.78 TP53 PTEN PIK3CA MAP2K2 HRAS BRAF
15
Show member pathways
12.73 TNFRSF10B PTEN PIK3CA MAP2K2 HRAS GNAS
16 12.69 PIK3CA MAP2K2 HRAS FGFR3 BRAF
17
Show member pathways
12.67 TP53 SMAD4 PTEN PIK3CA NFE2L2 MAP2K2
18
Show member pathways
12.66 TP53 PIK3CA MAP2K2 HRAS BRAF
19
Show member pathways
12.63 TP53 PTEN PIK3CA MAP2K2 HRAS GNAS
20
Show member pathways
12.59 TNFRSF10B PIK3CA MAP2K2 HRAS BRAF
21
Show member pathways
12.52 PTEN PIK3CA MAP2K2 HRAS
22
Show member pathways
12.51 TP53 PIK3CA MAP2K2 HRAS FGFR3
23
Show member pathways
12.48 PIK3CA MAP2K2 HRAS FGFR3
24
Show member pathways
12.47 TP53 PTEN PIK3CA MAP2K2 HRAS
25
Show member pathways
12.47 PTEN PIK3CA MAP2K2 HRAS BRAF
26
Show member pathways
12.47 TP53 PTEN PIK3CA MAP2K2 HRAS FGFR3
27
Show member pathways
12.45 PIK3CA MAP2K2 HRAS GNAS
28
Show member pathways
12.45 PIK3CA MAP2K2 HRAS BRAF
29
Show member pathways
12.44 PIK3CA MAP2K2 HRAS FGFR3 BRAF
30
Show member pathways
12.42 TP53 TNFRSF10B PTEN MIR210
31
Show member pathways
12.42 MAP2K2 HRAS GNAS BRAF
32 12.4 TP53 SMAD4 PIK3CA HRAS
33
Show member pathways
12.38 TP53 PIK3CA MAP2K2 HRAS GNAS
34 12.38 TP53 SMAD4 PTEN PIK3CA NFE2L2 MAP2K2
35
Show member pathways
12.37 PIK3CA MAP2K2 HRAS GNAS
36
Show member pathways
12.37 PTEN PIK3CA MAP2K2 HRAS
37 12.37 PIK3CA MAP2K2 GNAS BRAF
38
Show member pathways
12.32 PIK3CA HRAS FGFR3 BRAF
39
Show member pathways
12.3 TP53 MAP2K2 HRAS BRAF
40 12.3 TP53 PIK3CA MIR21 MAP2K2 HRAS BRAF
41
Show member pathways
12.29 PTEN MAP2K2 HRAS FGFR3
42
Show member pathways
12.27 PIK3CA MAP2K2 HRAS GNAS BRAF
43
Show member pathways
12.25 MAP2K2 HRAS GNAS BRAF
44 12.24 PTEN MAP2K2 HRAS BRAF
45 12.24 TP53 SMAD4 MAP2K2 GNAS BRAF
46
Show member pathways
12.23 PTEN PIK3CA MAP2K2 HRAS
47 12.21 TP53 SMAD4 PTEN BRAF
48 12.21 TP53 PTEN PIK3CA MAP2K2 HRAS
49
Show member pathways
12.2 TP53 MAP2K2 HRAS BRAF
50
Show member pathways
12.2 TP53 PIK3CA MAP2K2 HRAS BRAF

GO Terms for Squamous Cell Carcinoma, Head and Neck

Biological processes related to Squamous Cell Carcinoma, Head and Neck according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 gene silencing by miRNA GO:0035195 9.91 MIR98 MIR210 MIR21 MIR205 H19
2 MAPK cascade GO:0000165 9.78 MAP2K2 HRAS FGFR3 BRAF
3 negative regulation of ERK1 and ERK2 cascade GO:0070373 9.67 SMAD4 PTEN MIR21
4 positive regulation of apoptotic process GO:0043065 9.65 TP53 TNFRSF10B PTEN MIR21 ING3
5 cellular response to drug GO:0035690 9.58 TP53 NFE2L2 BRAF
6 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.55 PTEN MIR21 HRAS FGFR3 BRAF
7 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.46 TP53 MAP2K2
8 positive regulation of metalloendopeptidase activity GO:1904685 9.43 MIR21 MIR205
9 negative regulation of cell proliferation GO:0008285 9.43 TP53 SMAD4 PTEN MIR21 ING1 HRAS
10 regulation of axon regeneration GO:0048679 9.37 PTEN BRAF
11 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.32 MIR210 MIR21
12 positive regulation of gene expression GO:0010628 9.1 TP53 PTEN NFE2L2 MIR21 HRAS BRAF

Sources for Squamous Cell Carcinoma, Head and Neck

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....